PrEPVacc

African-led, European-supported HIV prevention project running in four countries in East and Southern Africa from 2018 to 2024

[MRC/UVRI and LSHTM Uganda Research Unit @MRC_Uganda]

Experts in virology, immunology and epidemiological research at the Unit have shared key insights from notable HIV studies on various platforms at the @AIDS_conference. We’re very honored to contribute to global discussions to improve health. #AIDS2024

[PrEPVacc @PrEPVacc]

“Our participants’ dedication to this study has been exemplary. They and their communities should be very proud of their efforts and their important contributions to the global effort to prevent HIV.” @PrEPVacc Trial Director, Dr Eugene Ruzagira, @MRC_Uganda

[PrEPVacc @PrEPVacc]

“Community engagement is imperative in all phases of research. In @PrEPVacc there have been positive community interactions so that people were well informed on developments, expectations, and transparency,” Xoliswa Nomvungu, Community Working Group at @MRCza Verulam, Durban

[PrEPVacc @PrEPVacc]

During the @PrEPVacc vaccine trial, counselling, promotion and provision of #PrEP were emphasised at every visit to all participants, with active follow-up regarding use. The study will now follow all participants for at least two years.

[PrEPVacc @PrEPVacc]

"The number of new infections has fallen throughout the six years we have been monitoring the HIV incidence in each study community," @PrEPVacc Trial Director, Dr Eugene Ruzagira, @MRC_Uganda

[PrEPVacc @PrEPVacc]

"The positive news for our communities is that repeated risk reduction counselling and use of proven HIV prevention tools helps people navigate their risks better."

[PrEPVacc @PrEPVacc]

HIV vaccines tested in @PrEPVacc fail to reduce infections. Results reported @iasociety #AIDS2024 show conclusively that neither of the two experimental vaccine regimens tested reduced HIV infections among the study population. https://t.co/8aK5sJgYu3

[MRC/UVRI and LSHTM Uganda Research Unit @MRC_Uganda]

Happy #InternationalWomensDay to the incredible women at @MRC_Uganda who inspire and lead with grace and strength. Your contributions to the Unit not only impact Uganda but ripple across the globe. We celebrate you!

#InspireInclusion #WD2024

[MRC/UVRI and LSHTM Uganda Research Unit @MRC_Uganda]

Today, we celebrate Dr. Sylvia Kusemererwa, a dedicated female scientist leading groundbreaking research at the Unit. She has coordinated clinical trials that have impacted policy change globally.

Read more about her: https://t.co/KXvioM4RJb

#WomenLedScience #CelebratingWomen

[SAMRC @MRCza]

Researchers from SAMRCs #HIV and Other Infectious Diseases Research Unit spoke to 150 participants from the Verulam site in Durban thanking them for their contribution in the PrEPVacc Trial update.

[SAMRC @MRCza]

Xoliswa is a nurse, an active volunteer & Community Working Group Member. Here she expresses her appreciation to SAMRC researchers for sharing the PrEPVacc study update at a Media Café hosted by AVAC. In a panel with Dr Ruzagira (UGA), Dr Kansiime (UGA) & Prof McCormack (UK).

[Channel Africa @channelafrica1]

[ON AIR]

🎧 @khumbza on #AfrikaTonight

🚨PrEPVacc recently announced that vaccinations have been stopped in its HIV Phase 2 prevention study.
Prof. Glenda Grey-SAMRC President & CEO joins us to discuss this

@SABCPlus app | DSTV 802 |
Stream: https://t.co/41XZ0YHdX3

[SAMRC @MRCza]

Neetha Morar, Research Manager, together with Sibusio Nhleko shared key messages to share with the community which included advocating for uptake of current prevention methods. Xoliswa Nomvungu, chair of the CWG, thanked the SAMRC, HIDRU (https://t.co/6UmpCdjCqi) team.

[SAMRC @MRCza]

Dr Nishanta Singh, PrEPVacc Principal Investigator (Verulam site), explained the study update to the community working group (CWG) members on the 5th December 2023, prior to public release.

[IAS - the International AIDS Society @iasociety]

African-led #HIV vaccine trials have been halted after "disappointing initial results".

The @PrEPVacc study concluded early as preliminary outcomes suggested limited effectiveness.

Read more in @guardian: https://t.co/oc4RZutJYu

[SAMRC @MRCza]

Experimental HIV vaccine regimens likely to be ineffective in preventing HIV acquisition, @PrEPVacc study reports
https://t.co/EZ5ID88M6Y

[SAMRC @MRCza]

@PrEPVacc announced that vaccinations have been stopped in its HIV Phase 2 prevention study of experimental vaccine regimens running in East and Southern Africa due to lack of demonstrated efficacy in preventing HIV acquisition.
https://t.co/0hbk3N3yUV

[IAS - the International AIDS Society @iasociety]

.@PrEPVacc announced today that it "has stopped further vaccinations as there is little or no chance of the trial demonstrating vaccine efficacy in preventing HIV acquisition". The IAS calls for stepping up #HIV vaccine R&D.

Read our statement here: https://t.co/UEjIveyr1o

[AVAC @HIVpxresearch]

Today the @PrEPVacc trial team announced at #ICASA2023 that they were stopping vaccinations after it was determined there was little chance the vaccines could stop HIV acquisition. Read AVAC's full response of the trial ending early here: https://t.co/AW1LGbu3T2

[NTV UGANDA @ntvuganda]

Prepvacc HIV prevention study halts vaccinations due to inefficacy in preventing HIV acquisition
#NTVNews

More Details | https://t.co/OXsbZ7JDkd